X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-06-17 | ESPR | Koenig Sheldon L. | Pres, CEO | S - Sale | $4.99 | -4,552 | 190,165 | -2% | -$22,719 | ||||||
2022-06-17 | ESPR | Warren Eric | Chief Commercial Officer | S - Sale | $4.90 | -256 | 53,654 | 0% | -$1,254 | ||||||
2022-06-02 | ESPR | Carroll J Martin | Dir | P - Purchase | $5.64 | +5,000 | 5,000 | New | +$28,180 | ||||||
2022-05-17 | ESPR | Warren Eric | Chief Commercial Officer | S - Sale | $5.98 | -196 | 53,910 | 0% | -$1,172 | ||||||
2022-03-17 | ESPR | Koenig Sheldon L. | Pres, CEO | S - Sale | $4.58 | -571 | 194,717 | 0% | -$2,615 | ||||||
2021-05-24 | ESPR | Biotech Target N V | 10% | P - Purchase | $20.22 | +100,000 | 4,477,964 | +2% | +$2,021,620 | ||||||
2021-05-19 | ESPR | Biotech Target N V | 10% | P - Purchase | $20.37 | +200,000 | 4,377,964 | +5% | +$4,073,960 | ||||||
| M | 2021-05-05 | ESPR | Biotech Target N V | 10% | P - Purchase | $20.21 | +230,000 | 4,177,964 | +6% | +$4,648,482 | |||||
2020-11-03 | ESPR | Biotech Target N V | 10% | P - Purchase | $25.31 | +200,000 | 3,947,964 | +5% | +$5,062,120 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |